Evaluation of Improvement in Skin and Nail Psoriasis in Bio-naive Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO-VIBRANT Study.

ABSTRACT:

Objective

To evaluate whether intravenous (IV) golimumab produces improvements in skin and nail symptoms that are concomitant with improvements in quality of life (QoL) and joint symptoms in patients with psoriatic arthritis.

Methods

Patients were randomized to either IV golimumab 2 mg/kg at weeks 0, 4, then every 8 weeks (q8w) through week 52 or placebo at weeks 0, 4, then q8w, with crossover to IV golimumab 2 mg/kg at weeks 24, 28, and then q8w through week 52. Assessments included Psoriasis Area and Severity Index (PASI), modified Nail Psoriasis Severity Index (mNAPSI), Dermatology Life Quality Index (DLQI), and American College of Rheumatology (ACR) rheumatoid arthritis response criteria.

Results

Through week 24, achievement of PASI 75/90/100 responses (P ≤ .0098)

SUBMITTER: Mease P 

PROVIDER: S-EPMC7672302 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature